Imunon, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Imunon, Inc. (IMNN) on June 13, 2025. The filing reports material changes in executive leadership, specifically the termination of the interim Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and compensation arrangements.
Material Changes
- Termination of Interim CFO: On June 13, 2025, the Company terminated the consulting agreement with Monomoy Advisors, LLC, and the service of David Gaiero as interim Chief Financial Officer, effective immediately.
- Appointment of New Interim CFO: Effective June 13, 2025, Kimberly Graper was appointed as the new interim Chief Financial Officer, serving as both principal financial officer and principal accounting officer.
Management Commentary and Compensation
Ms. Graper joined Imunon in October 2022 as Vice President of Finance and Corporate Controller. Under her existing employment agreement (Offer Letter dated September 20, 2022), she will continue to receive an annual base salary of $244,800 and is eligible for a target annual performance bonus of 30% of her base salary. The Company confirmed no family relationships or undisclosed material interests exist between Ms. Graper and other directors or officers.
Investor Verification Checklist
- Verify the transition timeline for financial reporting responsibilities between the outgoing and incoming CFO.
- Review the full text of the Offer Letter (Exhibit 10.1) for any additional compensation terms or severance provisions not detailed in the summary.
- Confirm the status of the Company's search for a permanent Chief Financial Officer, as the new appointee is serving in an interim capacity.